BIRLASOFT LIMITED has informed the Exchange about Transcript
BSOFT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Birlasoft reported Q4 FY26 revenue of INR 13,486 million (flat QoQ, up 2.4% YoY), with dollar revenue declining 3.7% QoQ to $145.3 million due to soft demand, client-specific issues in Life Sciences/MedTech, and fewer working days. Full-year FY26 revenue fell 6% in dollar terms to $597.5 million. However, the company delivered strong margin expansion: Q4 EBITDA margin improved to 18.5% and full-year margin reached 16.3% (up 333 bps from 13% in FY25), driven by exiting low-margin deals (~200 bps impact) and operational efficiencies. Normalized full-year PAT rose 27.6% YoY to INR 659.5 crore. The company signed deals worth $208 million TCV in Q4 (second consecutive quarter above $200M). Management acknowledged six quarters of revenue decline, attributed partly to client-specific issues in MedTech and upfront productivity benefits required in AI deals. They are betting on a turnaround with 30-40% increase in sales team strength by mid-FY27 and new leadership hires across AI, ERP, and Life Sciences verticals.
For shareholders, the margin expansion story is positive, but persistent revenue decline over six quarters is concerning. The company is investing heavily in sales to drive pipeline and order booking, with management hoping FY27 will be better. However, CFO indicated margins will normalize to 15%+ steady-state as investments ramp up, suggesting near-term margin pressure. The stock may see volatility given the growth-vs-margin trade-off.